Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Digital health tools

Topic: Risk, prevention and care in population studies

Plain-language summary

Background Parkinson's disease (PD) is associated with a host of nonmotor symptoms, including psychosis, cognitive impairment, depression, sleep disturbance, swallowing disorders, gastrointestinal symptoms, and autonomic dysfunction. Results A total of 148 articles, including RCTs, meta-analyses, and evidence-based reviews, were included in this review. However, the largest study to date found nortriptyline therapy to be efficacious compared with placebo, whereas paroxetine controlled release was not. The challenges associated with nonmotor symptoms must not be forgotten in light of the motor symptoms of PD, and treatment of nonmotor symptoms should be encouraged.

What this study adds

Evidence grade: High

This is a pooled review of 148 participants. This review covers treatment options for nonmotor symptoms of Parkinson's disease, including cognitive impairment, depression, and sleep disturbance. It notes that the largest study to date found nortriptyline efficacious compared with placebo, whereas paroxetine controlled release was not.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Wood, L. D., Neumiller, J. J., Setter, S. M., & Dobbins, E. K. (2010). Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease. The American journal of geriatric pharmacotherapy. https://doi.org/10.1016/j.amjopharm.2010.08.002

Vancouver

Wood LD, Neumiller JJ, Setter SM, Dobbins EK. Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease. The American journal of geriatric pharmacotherapy. 2010. doi:10.1016/j.amjopharm.2010.08.002. PMID: 20869620.

BibTeX

@article{wood2010-20869620,
  author  = {Wood, L. D. and Neumiller, J. J. and Setter, S. M. and Dobbins, E. K.},
  title   = {{Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease}},
  journal = {The American journal of geriatric pharmacotherapy},
  year    = {2010},
  doi     = {10.1016/j.amjopharm.2010.08.002},
  pmid    = {20869620},
  url     = {https://doi.org/10.1016/j.amjopharm.2010.08.002}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review covers treatment options for nonmotor symptoms of Parkinson's disease, including cognitive impairment, depression, and sleep disturbance. It notes that the largest study to date found nortriptyline efficacious compared with placebo, whereas paroxetine controlled release was not.

Study details

How this study scored 53/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 51 of the 96 points it could be judged on, which is 53 of 100. Total 53 of 100.51 of the 96 points we could judge = 53 of 100

Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. Scored zero for effect reported because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 51 of the 96 points we could judge it on, which is 53 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (The American journal of geriatric pharmacotherapy)
Journal's citation record 0 / 4 The American Journal of Geriatric Pharmacotherapy: journal h-index 73 (OpenAlex, 2026-10-29)
Study design 12 / 12 A meta-analysis pooling many studies
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2010 — within 20 year(s) of the newest study here
Sample size 2 / 4 148 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 4 / 7 Cited 74 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 4.1 citations a year over 18 year(s) since 2010
Impact for its field and year 3 / 6 Cited 5.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Erin K. Dobbins holds only 5 work(s), too few to judge a track record — left out of this score
Institution's track record 0 / 3 Washington State University Spokane: institution h-index 206 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 20869620)
Free to read 0 / 2 Behind a paywall — scores zero
Points 51 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 51 of the 96 points we could judge it on is 53 out of 100.
Total 53 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.

Related studies in Digital health tools from nearby years

Also tagged “lewy”

1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Digital health tools

See all studies in Digital health tools →